Palo Alto, Calif.
Schering-Plough Corp. is consolidating biopharma research operations in Palo Alto, Calif. Subsidiary Canji Inc. will be relocated to merge with Schering-Plough's DNAX Research Institute to create an integrated company called Schering-Plough Biopharma. The 68,000-sf facility, where DNAX is located, will be fully operational by the third quarter of 2005. Schering-Plough Biopharma will focus primarily on biologics research including monoclonal antibodies and therapeutic proteins.
